CINECA IRIS Institutional Research Information System

ABATE, Maria Lorena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.216
EU - Europa 7.551
AS - Asia 5.803
AF - Africa 220
SA - Sud America 202
OC - Oceania 159
Continente sconosciuto - Info sul continente non disponibili 14
Totale 23.165
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.838
CN - Cina 3.342
IT - Italia 1.400
DE - Germania 1.296
SE - Svezia 990
IE - Irlanda 590
FR - Francia 556
SG - Singapore 427
UA - Ucraina 394
JP - Giappone 388
GB - Regno Unito 328
RU - Federazione Russa 307
FI - Finlandia 281
KR - Corea 257
PL - Polonia 252
CA - Canada 251
IN - India 242
AT - Austria 234
VN - Vietnam 231
TR - Turchia 223
HK - Hong Kong 165
TW - Taiwan 163
DK - Danimarca 159
AU - Australia 156
GR - Grecia 156
ES - Italia 131
ID - Indonesia 123
BR - Brasile 115
NL - Olanda 115
MX - Messico 104
EG - Egitto 101
BE - Belgio 68
CH - Svizzera 47
IR - Iran 43
NO - Norvegia 43
RO - Romania 41
CZ - Repubblica Ceca 34
PT - Portogallo 34
PK - Pakistan 29
MY - Malesia 25
MU - Mauritius 23
TH - Thailandia 23
CO - Colombia 22
KE - Kenya 22
HU - Ungheria 21
SA - Arabia Saudita 21
IL - Israele 20
PH - Filippine 17
HR - Croazia 16
CL - Cile 15
EC - Ecuador 14
EU - Europa 14
UZ - Uzbekistan 14
AR - Argentina 13
IQ - Iraq 13
RS - Serbia 12
PE - Perù 11
SI - Slovenia 11
BG - Bulgaria 10
VE - Venezuela 10
ZA - Sudafrica 10
ET - Etiopia 8
GT - Guatemala 8
ZM - Zambia 8
CM - Camerun 7
BF - Burkina Faso 6
BY - Bielorussia 6
CV - Capo Verde 6
KH - Cambogia 6
CU - Cuba 5
MN - Mongolia 5
NG - Nigeria 5
AE - Emirati Arabi Uniti 4
CY - Cipro 4
KZ - Kazakistan 4
MA - Marocco 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
CR - Costa Rica 3
GH - Ghana 3
LV - Lettonia 3
MZ - Mozambico 3
NZ - Nuova Zelanda 3
SD - Sudan 3
YE - Yemen 3
CI - Costa d'Avorio 2
EE - Estonia 2
GE - Georgia 2
GM - Gambi 2
LU - Lussemburgo 2
MD - Moldavia 2
MK - Macedonia 2
PS - Palestinian Territory 2
QA - Qatar 2
SR - Suriname 2
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
CD - Congo 1
Totale 23.154
Salva come PNG Salva come JPEG
Città #
Chandler 1.081
Beijing 988
Ann Arbor 763
Dublin 582
Fairfield 563
Ashburn 418
Houston 371
Redwood City 343
Singapore 318
Shanghai 304
Wilmington 295
Woodbridge 293
Villeurbanne 279
Dearborn 276
Torino 260
Jacksonville 230
Guangzhou 225
Nyköping 219
Seattle 213
Vienna 204
Pisa 196
Medford 185
Princeton 174
Cambridge 166
Warsaw 140
Ottawa 137
Fremont 131
Dong Ket 117
Nanjing 116
Hangzhou 107
Wuhan 95
Jakarta 93
Tokyo 92
New York 90
Taipei 89
Chengdu 86
West Jordan 79
Turin 73
Rome 72
Boston 69
Santa Clara 62
Boardman 56
Istanbul 51
Sydney 50
Chongqing 49
Hefei 49
London 48
Milan 48
Toronto 45
Brussels 44
Zhengzhou 44
Munich 42
San Diego 41
Seoul 41
Norwalk 39
Jinan 36
Los Angeles 36
Pune 36
Düsseldorf 35
Kunming 35
Washington 35
Central 33
Ankara 32
Changsha 32
Hanoi 32
Shenyang 32
Tianjin 32
Helsinki 31
Changchun 30
Cairo 29
Duncan 29
Central District 28
Amsterdam 27
San Mateo 26
Berlin 25
Naples 25
Hong Kong 24
Delhi 23
Athens 22
Ho Chi Minh City 22
Bucharest 21
Silver Spring 21
Stavanger 21
Moscow 20
Phoenix 20
Falls Church 19
Frankfurt am Main 19
Paris 19
Bengaluru 18
Bologna 18
Melbourne 18
Mumbai 18
Nürnberg 18
Rochester 18
Fuzhou 17
Hebei 17
Madrid 17
Qingdao 17
São Paulo 17
Xiamen 17
Totale 12.358
Salva come PNG Salva come JPEG
Nome #
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.754
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection 1.011
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 985
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 968
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 652
FibroGENE: A gene-based model for staging liver fibrosis 522
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 513
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 438
Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin for hepatocellular carcinoma detection 362
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 360
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 356
Chronic hepatitis B therapy: available drugs and treatment guidelines. 334
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 310
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 268
Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. 266
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 259
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis 252
Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers 223
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 201
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B 197
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 196
Serum heat shock protein 27 is a new circulating biomarker for hepatocellular carcinoma 183
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 176
The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B 175
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 173
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 164
ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. 161
Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. 160
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 160
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 150
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 147
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 146
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 145
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. 140
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 138
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 137
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 135
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. 134
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 134
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 133
'e' antigen defective hepatitis B virus and course of chronic infection. 131
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 131
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 130
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 130
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. 130
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 129
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 129
Italian blood donors with anti-HBc and occult hepatitis B virus infection 128
Antibodies against GOR in patients undergoing orthotopic liver trasplantation (OLT) 127
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 125
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort 124
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 124
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 123
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 123
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 120
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 119
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 116
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 116
CLINIC EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HBV CHRONIC INFECTION 115
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 115
Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence 113
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 113
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease 112
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 110
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 110
Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. 109
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 108
Bile acids composition modulate insulin resistance in non-diabetic patients with NAFLD 108
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 107
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 107
CLINICAL EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HBV INFECTION 106
ETIOLOGY OF CHRONIC LIVER DISEASES IN THE NORTHWEST OF ITALY, 1998 THROUGH 2014 106
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 106
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 105
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 105
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 104
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 104
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 103
la reinfezione virale nel post -trapianto 103
Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. 103
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 102
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B 101
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C 100
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 99
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 99
Liver transplant for viral hepatitis. Recurrence of reinfection 98
Inactive hepatitis B virus carriers: a favourable clinical condition 98
PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C 98
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 97
Serological characterization of occult HBV infection in liver donors 96
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 96
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 93
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 93
Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C. 90
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 90
Prevalence of hepatitis C virus/hepatitis G virus co-infection in Turin: updated data ten years later. 89
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined cytokeratin-18 apoptotic fragment and elastometry 89
Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease 89
Increased Pre-Hepatic Insulin Levels Are Directly Related to Nash, Fibrogenesis and Fibrosis in Non Diabetic NAFLD Patients but Not in Type 2 Diabetes 88
Totale 19.875
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.133
article - articoli 0
book - libri 0
conference - conferenze 18.317
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.450
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.648 0 0 0 321 220 506 289 241 335 341 202 193
2020/20213.122 243 308 190 214 310 243 253 164 282 278 254 383
2021/20223.846 180 212 176 384 309 239 341 346 236 446 560 417
2022/20233.931 354 312 164 323 317 768 318 293 397 210 245 230
2023/20243.130 308 342 218 246 216 408 180 307 62 292 227 324
2024/2025936 185 386 289 76 0 0 0 0 0 0 0 0
Totale 23.904